Renalytix (Renalytix) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Renalytix 3-Year Revenue Growth Rate?

Renalytix's Revenue per Share for the three months ended in Mar. 2024 was $0.01.

During the past 12 months, Renalytix's average Revenue per Share Growth Rate was -55.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Renalytix's 3-Year Revenue Growth Rate

For the Health Information Services subindustry, Renalytix's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's 3-Year Revenue Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Renalytix's 3-Year Revenue Growth Rate falls into.

Renalytix 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Renalytix (NAS:RNLX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Renalytix 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Renalytix's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (Renalytix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

RTNXF:USA RENX:UK 2O9A:Germany 2O9A:Germany 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Executives

Howard Jr Doran	officer: Chief Business Officer	C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain	officer: President	NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc.	10 percent owner	150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills	director, 10 percent owner	C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling	officer: Chief Financial Officer	C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc.	10 percent owner	ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount	10 percent owner	ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming	director, officer: Chief Technical Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough	director, officer: Chief Executive Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE